Apr 20, 2025 | Disease Prevention, Weight Loss
Eli Lilly has announced promising results from its first Phase 3 clinical trial for orforglipron, a once-daily oral GLP-1 receptor agonist. The trial results show significant reductions in both blood sugar (A1C levels) and body weight among adults with type 2...
Mar 5, 2025 | Articles, Disease Prevention, Weight Loss
Introduction: The Hidden Epidemic of Physical Inactivity In today’s modern world, physical inactivity has become one of the most significant yet underestimated health risks. With more people leading sedentary lifestyles—working at desks, driving instead of walking,...
Dec 3, 2024 | Disease Prevention, Heart Health
Atherosclerosis, a form of cardiovascular disease (ASCVD), affects millions of people worldwide and is among the leading causes of death. While many consider heart disease to be a risk only in older age, studies reveal that atherosclerosis can begin early, progressing...
